Loading…
AIM ImmunoTech Inc. is projected to rise to $0.3068 by 2027, a +8% move from its current price of $0.283. AIM is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $0.2607 | $0.283 | $0.3072 | 0.00% |
| Jul 14 | $0.252 | $0.283 | $0.3178 | 0.00% |
| Jul 15 | $0.2455 | $0.283 | $0.3261 | -0.01% |
| Jul 16 | $0.2402 | $0.283 | $0.3334 | -0.01% |
| Jul 17 | $0.2356 | $0.283 | $0.3399 | -0.01% |
| Jul 18 | $0.2315 | $0.283 | $0.3459 | -0.01% |
| Jul 19 | $0.2278 | $0.283 | $0.3515 | -0.02% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.2278 | $0.283 | $0.3515 | -0.02% |
| Week 2 | $0.2082 | $0.2829 | $0.3845 | -0.03% |
| Week 3 | $0.1943 | $0.2829 | $0.4118 | -0.05% |
| Week 4 | $0.1833 | $0.2828 | $0.4364 | -0.07% |
| Week 5 | $0.1741 | $0.2828 | $0.4592 | -0.09% |
| Week 6 | $0.1662 | $0.2827 | $0.4809 | -0.10% |
| Week 7 | $0.1592 | $0.2827 | $0.5017 | -0.12% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
AIM ImmunoTech Inc. is a healthcare company focused on immuno-pharma. It engages in the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States.
The company’s flagship products are Ampligen (rintatolimod), a drug of large macromolecular double-stranded ribonucleic acid molecules to treat chronic fatigue syndrome; and Alferon N Injection (Interferon alfa), a purified, natural-source, glycosylated, multi-species alpha interferon product for the treatment of genital warts. It is also developing Ampligen for potential treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. The company was formerly known as Hemispherx Biopharma, Inc.
and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech was founded in 1966 and is headquartered in Ocala, Florida.
AIM ImmunoTech Inc., trading under the symbol AIM, is a healthcare company with a focus on immuno-therapeutics. The current price is $0.283, and the company has a market cap of $7.85M and is ranked 5151 by market capitalization. The long-term price outlook shows potential upside from the current level, with projected averages rising across years and a strong upper-bound trajectory by 2050.
A major floor 18.7% below — a decisive break under it would weaken the trend.
Price is testing support right now (1.1% away) — a key level to hold.
The nearest ceiling, 218.0% above — a clean break opens room to run.
A major ceiling 291.0% above — clearing it would confirm fresh momentum.
Key AIM support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of AIM market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $0.294 | Sell | $0.2907 | Sell |
| MA 10 | $0.294 | Sell | $0.3057 | Sell |
| MA 20 | $0.343 | Sell | $0.3407 | Sell |
| MA 50 | $0.4036 | Sell | $0.4253 | Sell |
| MA 100 | $0.5665 | Sell | $0.6778 | Sell |
| MA 200 | $1.11 | Sell | $2.15 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 39.73 | Neutral |
| Stoch RSI (14) | 22.95 | Neutral |
| CCI (20) | -85.71 | Neutral |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -0.00 | Sell |
| ROC (12) | -22.22 | Sell |
| Bollinger %B (20,2) | 0.21 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | -1.39 | Sell |
| Awesome (5,34) | -0.11 | Sell |
| Ultimate (7,14,28) | 42.84 | Neutral |
| Momentum (10) | -0.08 | Sell |
| Aroon Osc (25) | -100.00 | Sell |
| Hull MA (9) | 0.29 | Sell |
| ADX (14) | 16.97 | Neutral |
| ATR (14) | 0.03 | Info |
The near-term technical picture remains bearish, with RSI14 at 40 and the price trading below notable moving averages. The SMA50 stands at $0.4036 and the SMA200 at $1.11, indicating that near-term momentum is modest at best. The stock finds support at $0.28 and faces resistance at $0.90, while the 30-day price range runs from $0.1649 to $0.4858.
Annualized volatility is high at 200%, underscoring elevated risk.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.23 | $0.283 | $0.3745 | 0% | Neutral | |
| $0.2226 | $0.3068 | $0.4572 | +8% | Neutral | |
| $0.2737 | $0.4008 | $0.6365 | +42% | Bullish | |
| $0.2711 | $0.4183 | $0.6974 | +48% | Bullish | |
| $0.2763 | $0.447 | $0.7757 | +58% | Bullish | |
| $0.2142 | $0.3621 | $0.6506 | +28% | Bullish | |
| $0.174 | $0.3069 | $0.5684 | +8% | Neutral | |
| $0.2237 | $0.4108 | $0.7821 | +45% | Bullish | |
| $0.2438 | $0.4658 | $0.9092 | +65% | Bullish | |
| $0.2616 | $0.5195 | $1.04 | +84% | Bullish | |
| $0.2454 | $0.5454 | $1.20 | +93% | Bullish | |
| $0.3946 | $0.8769 | $2.02 | +210% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $0.23 | $0.283 | $0.3271 | +0.00% |
| August 2026 | $0.2128 | $0.2577 | $0.3251 | -8.93% |
| September 2026 | $0.2299 | $0.2824 | $0.3637 | +9.56% |
| October 2026 | $0.2351 | $0.2923 | $0.383 | +3.51% |
| November 2026 | $0.2185 | $0.2746 | $0.365 | -6.07% |
| December 2026 | $0.2191 | $0.278 | $0.3745 | +1.24% |
Click any year to see its month-by-month AIM forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, AIM could reach as high as $0.3745, with a base case around $0.283 and support toward $0.23 — roughly 0% from $0.283. Price action looks broadly range-bound.
Expect AIM to range from $0.2226 to $0.4572 through 2027. The $0.3068 average target implies a +8% move from current prices. That is up +8% on the projected 2026 average. A consolidation phase looks the most probable path here.
The AIM price prediction for 2028 points to an average of $0.4008 (low $0.2737, high $0.6365) — a potential gain of +42% on today's $0.283. Momentum favours further upside here.
In 2029, AIM is projected to trade between $0.2711 and $0.6974, averaging $0.4183 — a potential gain of +48% from today's $0.283. That is up +4% on the projected 2028 average. Buyers look set to stay in control over this stretch.
AIM ImmunoTech Inc.'s 2030 outlook centres on $0.447, within a $0.2763 to $0.7757 range. That is up +7% on the projected 2029 average. That marks a +58% change versus current levels. Momentum favours further upside here.
By 2031, AIM could reach as high as $0.6506, with a base case around $0.3621 and support toward $0.2142 — roughly +28% from $0.283. Buyers look set to stay in control over this stretch.
Expect AIM to range from $0.174 to $0.5684 through 2032. The $0.3069 average target implies a +8% move from current prices. That is -15% versus the projected 2031 average. Price action looks broadly range-bound.
The AIM price prediction for 2033 points to an average of $0.4108 (low $0.2237, high $0.7821) — a potential gain of +45% on today's $0.283. Buyers look set to stay in control over this stretch.
In 2034, AIM is projected to trade between $0.2438 and $0.9092, averaging $0.4658 — a potential gain of +65% from today's $0.283. That is up +13% on the projected 2033 average. Momentum favours further upside here.
AIM ImmunoTech Inc.'s 2035 outlook centres on $0.5195, within a $0.2616 to $1.04 range. That is up +12% on the projected 2034 average. That marks a +84% change versus current levels. Buyers look set to stay in control over this stretch.
By 2040, AIM could reach as high as $1.20, with a base case around $0.5454 and support toward $0.2454 — roughly +93% from $0.283. Momentum favours further upside here.
Expect AIM to range from $0.3946 to $2.02 through 2050. The $0.8769 average target implies a +210% move from current prices. That is up +61% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in AIM today (≈ 3,533.568905 AIM) could be worth
$3,098.41
+$2,098.41 (+210%) by 2050 · US Dollar
Based on the average projected AIM price of $0.88 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in AIMwould be worth at today's price.
$1,000 invested in AIM on Jul 10, 2025 (≈ 110.149571 AIM) would be worth
$31.17
-$968.83 (-96.9%) today · 0.03× · US Dollar
Based on a AIM entry price of $9.08 vs. today's $0.283.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $0.28 | $1,010.71 | +1.1% |
| 1 month ago | $0.44 | $643.18 | -35.7% |
| 3 months ago | $0.52 | $544.23 | -45.6% |
| 6 months ago | $1.21 | $233.42 | -76.7% |
| 1 year ago | $9.08 | $31.17 | -96.9% |
| All time (5.0y) ago | $198.84 | $1.42 | -99.9% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our AIM forecast.
Our base-case forecast reaches $0.57 around 2050.
Implied market cap at $0.57: $15.8M
The multi-year forecast shows a bullish path in several years, with key milestones at 2030 and beyond. In 2026, the average price is $0.283 with a min of $0.23 and a max of $0.3755 (ROI 0%). By 2030, the average price is projected at $0.4464 with a max of $0.7748 and a min of $0.276, implying a 57.7% ROI and a bullish sentiment.
The forecast continues with 2031 at $0.3613 average (ROI 27.7%), 2032 at $0.3078 (ROI 8.8%), through 2035 at $0.52 (ROI 83.8%), 2040 at $0.5451 (ROI 92.6%), and 2050 at $0.8789 (ROI 210.6%), all labeled bullish in the majority of these years. The path suggests meaningful upside potential over the long term, though early years show more modest or flat returns and some neutral years.
Tap a question to reveal the answer.
Avg $0.4464, min $0.276, max $0.7748; ROI 57.7%; sentiment BULLISH.
The forecast shows average prices rising from the current $0.283 toward $0.4464 by 2030 and $0.8789 by 2050, with ROIs of 57.7% (2030) and 210.6% (2050) and bullish sentiment in multiple years, though there are neutral years and risks.
Yes—2035 max $1.04 and 2040 max $1.20 indicate potential to reach and exceed $1.00, though these are not guarantees.
Bearish sentiment with RSI 14 at 40. The stock trades below the SMA50 of $0.4036 and the SMA200 of $1.11, with support at $0.28 and resistance at $0.90; 30-day range is $0.1649 to $0.4858.
Current price is $0.283 and market cap is $7.85M, with a rank of 5151.
AIM ImmunoTech Inc. Community Discussion
0Share your AIM ImmunoTech Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.